Lexeo Therapeutics

Senior Director, Regulatory Strategy

Lexeo Therapeutics  •  New York City, NY (Hybrid)  •  18 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.
46
AI Success™

Job Description

The Senior Director, Regulatory Strategy will provide global regulatory leadership for AAV gene therapy development programs with an emphasis on early-stage clinical development. This role is responsible for defining and executing integrated regulatory strategies that align with corporate objectives, development timelines, and evolving global regulatory expectations for gene therapy products.

The ideal candidate will have deep experience leading global regulatory programs and extensive interaction with FDA, EMA, and other major health authorities. Strong preference will be given to candidates who also have regulatory CMC experience that could fill a dual role leading regulatory CMC.

Primary Responsibilities

  • Function as the global regulatory lead for early stage programs and participate in and advise global development teams
  • Define and lead the Regulatory strategy for early-stage gene therapy programs (pre-IND through Phase 1/2)
  • Lead preparation for and participation in global health authority interactions, including FDA (CBER), EMA, and other regional agencies
  • Lead the strategy and preparation of key regulatory objectives and documents such as Fast Track, RMAT, PRIME, and health authority meetings (INTERACT, Pre-IND, PDUFA meetings, scientific advice, etc.).
  • Proactively identify and communicate potential risks and define mitigation strategies
  • Monitor the evolving regulatory landscape for gene therapy and proactively advise internal stakeholders on global regulatory guidelines and requirements
  • Lead and manage the preparation and publication of regulatory submissions
  • Oversee regulatory activities conducted by CROs to ensure alignment with overall strategy

Additional Potential Regulatory CMC Responsibilities

  • Provide regulatory leadership for CMC strategy, particularly for AAV vector manufacturing, analytical control strategies, comparability, and lifecycle changes
  • Partner closely with CMC, technical operations, and quality teams to align regulatory expectations with manufacturing realities
  • Lead or contribute to regulatory strategies for:
  • Process development and scale‑up
  • Control strategy evolution
  • Manufacturing changes and comparability assessments
  • Interpret and apply evolving global guidance related to gene therapy CMC

Required Skills and Qualifications

  • Advanced degree in a scientific discipline is strongly preferred
  • Minimum 10 years of experience in Regulatory Affairs
  • Proven experience with global regulatory submissions (IND/CTA/BLA)
  • Direct experience with FDA and EMA meetings and interactions
  • Strong leadership experience
  • Excellent interpersonal and verbal and written communication skills; strong presentation skills
  • Excellent planning and organizational skills
  • Ability to travel monthly to NY HQ if not local to the area

Strongly Preferred Qualifications

  • Regulatory CMC experience, particularly with gene therapy or other biologics
  • Familiarity with accelerated pathways (RMAT, PRIME, Breakthrough Therapy)
  • Experience in rare disease development
  • Prior experience in a biotech or emerging company environment

About LEXEO
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.

Lexeo Therapeutics

About Lexeo Therapeutics

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.

For more information, please visit www.lexeotx.com.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
New York, New York
Year Founded
2018
Social Media